RADIAL has recruited its first remote patient

A huge milestone for the project and for the future of clinical trials

Utrecht, November 3, 2023

We are very happy to announce that our Clinical Trial RADIAL has enrolled the first patient in the remote arm. This means that we have our first patient that will conduct the clinical trial fully remote, @home without going to the study site at all.

We consider this is a huge milestone for the project and for the future of clinical trials!

In short:

Trials@Home is a publicly funded consortium in which Industry and Academia work together to reshape clinical trial design by investigating, developing and piloting standards and recommendations to decentralise aspects of clinical trials.

RADIAL, a proof-of concept study, is conducted as part of Trials@Home. The project’s consortium partners have worked together for nearly four years in consultation with three advisory bodies (a Patient Expert Panel, an External Stakeholder Platform and a Scientific Advisory Board) and many more external stakeholders to explore the concept of decentralised clinical trial approaches, or DCTs. This collaborative, co-creational process has included an inventory and analysis on technologies and best practice approaches within the DCT field, an exploration of the legal, regulatory, quality, and ethical landscape of DCTs, and consultations with relevant stakeholders including patient representatives and regulatory and ethical bodies. This work has informed the design and operational setup of RADIAL.

The study is seen as important to help to change the way how clinical trials are being conducted in future. The Lancet recently made a video about the future of clinical research. Please check-out the video in which a spot was also reserved for Trials@Home in which Mira Zuidgeest (Sponsor of Radial) speaks about Radial from min 4:23 onwards https://trialsathome.com/the-future-of-medical-research/

If you would like to check out more about Trials@Home or RADIAL, please go to


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831458. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Notes for editors – not for publication
If you would like more information, please contact the spokesperson at the UMC Utrecht.
Joris Prinssen: +31 6 2571 0234